Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

Abstract:

BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects. RESULTS:Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load. CONCLUSIONS:The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

subject

Has Abstract

pub_date

2003-02-01 00:00:00

pages

17-26

issue

1

eissn

1359-6535

issn

2040-2058

journal_volume

8

pub_type

杂志文章
  • Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

    abstract:BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3169

    authors: Lee SH,Cheon GJ,Kim HS,Kim SG,Kim YS,Jeong SW,Jang JY,Kim BS,Jun BG,Don Kim Y,Jun DW,Sohn JH,Kim TY,Lee BS

    更新日期:2018-01-01 00:00:00

  • Experience with nevirapine in previously treated HIV-1-infected individuals.

    abstract:OBJECTIVE:To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals. DESIGN:Retrospective observational cohort-study in 13 HIV-outpatient clinics in The Netherlands. METHODS: MAIN OUTCOME MEASURES:p...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Wit FW,Dutch HIV-treating physicians.

    更新日期:2000-12-01 00:00:00

  • Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

    abstract:BACKGROUND:Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (NAMs) can affect response to treatment with NRTIs and might also result in HIV-1 with reduced replication capacity. METHODS:A large commercial HIV-1 database (n=60,487) was analysed for the prevalence of NAMs, antiviral drug susceptibil...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: McColl DJ,Chappey C,Parkin NT,Miller MD

    更新日期:2008-01-01 00:00:00

  • The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

    abstract:BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2015

    authors: Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

    更新日期:2012-01-01 00:00:00

  • Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy.

    abstract:BACKGROUND:Damage to mitochondria (mt) is a major side effect of highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI). Such damage is associated with the onset of lipodystrophy in HAART-treated HIV+ patients. To further investigate mt changes during this syndrom...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Galluzzi L,Pinti M,Guaraldi G,Mussini C,Troiano L,Roat E,Giovenzana C,Nemes E,Nasi M,Orlando G,Salomoni P,Cossarizza A

    更新日期:2005-01-01 00:00:00

  • Successful therapy of cyclosporin A in pityriasis lichenoides et varioliformis acuta preceded by hand, foot and mouth disease.

    abstract::To our knowledge, there are no previously published cases of enteroviral infection complicated by pityriasis lichenoides et varioliformis acuta (PLEVA). A 30-year-old woman is reported with a severe form of PLEVA, preceded by hand, foot and mouth disease. Immunosuppressive treatment with cyclosporin A resulted in rapi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3012

    authors: Lis-Święty A,Michalska-Bańkowska A,Zielonka-Kucharzewska A,Pypłacz-Gumprecht A

    更新日期:2016-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • The host-pathogen interaction during HBV infection: immunological controversies.

    abstract::HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1620

    authors: Bertoletti A,Maini MK,Ferrari C

    更新日期:2010-01-01 00:00:00

  • The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

    abstract:BACKGROUND:Studies of the effects of antiretroviral drugs on lipid metabolism are limited by the availability of suitable models. We have thus developed an animal model utilising Göttingen mini-pigs. The normal lipid metabolism of mini-pigs closely reflects that of humans and they are expected to have similar reactions...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1509

    authors: Petersen E,Mu H,Porsgaard T,Bertelsen LS

    更新日期:2010-01-01 00:00:00

  • Finding a role for zalcitabine in the HAART era.

    abstract::Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. More widespread use of zalcitabine has been limited by a number of factors including peripheral neuropathy and three times daily dosing. However, screening for the risk factors for peripher...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Moyle GJ,Gazzard BG

    更新日期:1998-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract::Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP3245

    authors: Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期:2018-01-01 00:00:00

  • HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

    abstract:BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2938

    authors: Gomes-Gouvêa MS,Ferreira AC,Teixeira R,Andrade JR,Ferreira AS,Barros LM,Rezende RE,Nastri AC,Leite AG,Piccoli LZ,Galvan J,Conde SR,Soares MC,Kliemann DA,Bertolini DA,Kunyoshi AS,Lyra AC,Oikawa MK,de Araújo LV,Carril

    更新日期:2015-01-01 00:00:00

  • Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

    abstract:BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2671

    authors: Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

    更新日期:2013-01-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract:BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期:2009-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract:BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP3205

    authors: Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期:2018-01-01 00:00:00

  • Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study.

    abstract:BACKGROUND:In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2501

    authors: Kromdijk W,Mulder JW,Smit PM,Ter Heine R,Beijnen JH,Huitema AD

    更新日期:2013-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract:BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期:2005-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract::Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1671

    authors: Llibre JM

    更新日期:2010-01-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract:OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期:2003-12-01 00:00:00

  • Preventing and treating secondary bacterial infections with antiviral agents.

    abstract::Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1730

    authors: McCullers JA

    更新日期:2011-01-01 00:00:00

  • Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.

    abstract::Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chan HL,Wong VW,Hui AY,Tsang SW,Chan JL,Chan HY,Wong GL,Sung JJ

    更新日期:2006-01-01 00:00:00

  • The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.

    abstract::The hepatitis C virus (HCV) NS3 protein contains a serine proteinase domain implicated in the maturation of the viral polyprotein. NS3 forms a stable heterodimer with NS4A, a viral membrane protein that acts as an activator of the NS3 proteinase. The three-dimensional structure of the NS3 proteinase complexed with an ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: De Francesco R,Pessi A,Steinkühler C

    更新日期:1998-01-01 00:00:00

  • Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

    abstract::The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Matsumoto K,Ogawa N,Nerome K,Numazaki Y,Kawakami Y,Shirato K,Arakawa M,Kudoh S,Shimokata K,Nakajima S,Yamakido M,Kashiwagi S,Nagatake T

    更新日期:1999-01-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract:BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期:2008-01-01 00:00:00

  • Antiviral therapy reduces risk of haemorrhagic stroke in patients with HCV infection: a nationwide cohort study.

    abstract:BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3172

    authors: Lin MS,Chung CM,Lin WY,Wei KL,Wang J,Lee YY,Hu JH,Tung TH,Lin YS

    更新日期:2018-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00

  • Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

    abstract:OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

    更新日期:2006-01-01 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期:2006-01-01 00:00:00

  • Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.

    abstract:BACKGROUND:Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. METHODS:We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1557

    authors: Glesby MJ,Hoover DR,Shi Q,Danoff A,Howard A,Tien P,Merenstein D,Cohen M,Golub E,Dehovitz J,Nowicki M,Anastos K

    更新日期:2010-01-01 00:00:00

  • In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

    abstract::Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

    更新日期:2000-09-01 00:00:00